Werewolf Therapeutics Announces Merger Agreement to Combine with Ambros

What Happened
Werewolf Therapeutics, Inc. (HOWL) announced on August 21, 2026 that it entered into a definitive Agreement and Plan of Merger to merge Ambros Therapeutics, Inc. into a Werewolf subsidiary, with Ambros surviving as a wholly owned subsidiary of Werewolf. The filing also discloses a concurrent PIPE securities purchase agreement for aggregate gross proceeds of $150.0 million and related pre-funded warrants. The companies plan to file a Form S-4 and seek stockholder approvals; closing is subject to customary conditions including stockholder votes, listing approvals and receipt of PIPE proceeds.

Key Details

• Filing date: August 21, 2026; transaction structured to qualify as a tax-free reorganization for U.S. federal tax purposes.
• Concurrent PIPE Financing: $150.0 million aggregate purchase price; certain investors may receive pre-funded warrants (exercise price $0.001). Closing expected immediately prior to the merger.
• Pro forma ownership (expected, fully diluted, subject to adjustments): pre‑merger Werewolf holders ~6.8%, pre‑merger Ambros holders ~71.7%, PIPE investors ~21.5%; assumptions include Werewolf valuation of $47.5M and Ambros valuation of $500M.
• Closing conditions include: Ambros and Werewolf stockholder approvals, effectiveness of Form S-4, Nasdaq listing approvals, Securities Purchase Agreement in effect with at least $100M cash proceeds received (net of expenses), and Final Werewolf Net Cash > $0.
• Contingent Value Rights (CVRs): Werewolf will issue non-transferable CVRs to current Werewolf stockholders for potential cash payments tied to legacy assets WTX-124 and WTX-330; CVRs carry no voting rights and may yield no payment.
• Governance/support: Ambros stockholders holding ~71.3% have entered support agreements; Werewolf officers/directors holding ~1.4% have support agreements. Ambros insiders agreed to 180‑day lock-ups on securities received.
• Termination fees: Ambros may owe Werewolf $20.0M in certain termination scenarios; Werewolf may owe Ambros $1.9M in certain scenarios.
• Registration rights: combined company to file resale registration for PIPE securities within 45 days and use best efforts to have it effective promptly (subject to SEC review timelines).

Why It Matters
This 8-K signals a major strategic combination where Ambros becomes the dominant equity holder of the combined company (per pro forma estimates). The $150M PIPE provides committed capital tied to closing, but the transaction still requires both companies’ stockholder approvals, an effective S-4, Nasdaq listing approvals, and satisfaction of other closing conditions. Werewolf holders receive CVRs for specific legacy programs (WTX-124 and WTX-330), but those CVRs may never pay out. Investors should watch shareholder vote notices, the Form S-4 filing and effectiveness, the final PIPE pricing/closings, and any changes to the expected ownership mix or closing conditions.